9 results about "Diphtheria toxin" patented technology

The present invention provides a method for treating or inhibiting a myeloproliferative tumor (MPN) in a subject in need thereof, the method comprising administering to the subject a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) and one or more Jak inhibitors and / or one or more hypomethylating agents.

The invention discloses a pharmaceutical composition and application thereof, the pharmaceutical composition comprises a recombinant protein and an HIV virus invasion inhibitor, and the recombinant protein comprises: 1) an scFV of an anti-CD3 antibody; and 2) diphtheria toxin.

The present disclosure provides, in part, a method of treating an autoimmune disease in a subject by reducing the number of pDCs through administration of a human interleukin-3 (IL-3)-diphtheria toxin conjugate (DT-IL3). The disclosure also generally relates to methods of monitoring the effectiveness of therapy in subjects receiving DT-IL3 for treating an autoimmune disease, and methods of determining continuing treatment of subjects receiving DT-IL3 for treating an autoimmune disease. The disclosure also provides pharmaceutical compositions of DT-IL3 for use in such methods.

The invention relates to preparation and application of an engineering virus with high tumor specificity and high killing efficiency. Specifically, the invention relates to a recombinant oncolytic virus based on HSV-1 transformation, which is mainly characterized in that a diphtheria toxin A subunit (DT-A) expression cassette driven by a tumor specific promoter (such as Survivin) is inserted into an ICP6 gene coding region of wild type HSV-1, so that specific recognition and efficient direct killing of tumor cells are realized, and the expression cassette is a recombinant oncolytic virus. And hepatic targeting delivery is realized by matching with red blood cells treated by cationic polymers.

The invention discloses teasel glycosyl transferase and application thereof in production of alpha-hederaoside and teasel saponin B. The amino acid sequence of the teasel glycosyl transferase is shown as SEQ ID NO.1, and the nucleotide sequence of the coding gene of the teasel glycosyl transferase is shown as SEQ ID NO.2. The invention further discloses a preparation method of the teasel glycosyl transferase. After the glycosyl transferase is subjected to prokaryotic expression, a series of triterpenoid saponins can be catalyzed to be converted into triterpenoid saponin-3-(2-O)-glycoside products in a glycosylation manner, and the triterpenoid saponin-3-(2-O)-glycoside products comprise alpha-hederin and dipsacus asper saponin B. The discovery of the dipsacus asper triterpenoid saponin glycosyltransferase provides more optional biological elements for the biosynthesis of natural products, and has a good application prospect.

Cytotoxin-CCL8 peptide constructs that include a cytotoxin linked to a CCL8 peptide and uses thereof. The cytotoxin can include a cytotoxic peptide such as a diphtheria toxin peptide. The constructs can be used to treat CCL8-related diseases, such as cancer, graft versus host disease (GVHD), microbial infections, and pulmonary fibrosis acute respiratory distress syndrome (ARDS), among others.

The application discloses a fermentation process of gonadotropin-releasing hormone hexamer-diphtheria toxin mutant CRM197, and the process comprises the following steps: screening of a fermentation medium and optimization of fermentation conditions. The fermentation medium comprises yeast extract powder, tryptone and NaCl, and the optimization of the fermentation process comprises culture temperature, an inducing agent, concentration of the inducing agent, culture time after induction, adjustment mode of pH of the fermentation liquor, stirring speed, ventilation amount and the like. The fermentation process has the advantages of low production cost, short production cycle (only 12-15 hours are needed), improved expression amount of the target protein per unit of bacteria, and realized high-efficiency expression of the target protein. The GnRH6-CRM197 prepared by the application can be used for immunocastration of various mammals, and has the values of further research and development and good industrialization prospect.

The present invention refers to a fusion protein or conjugate comprising or consisting of: a) a Diphtheria toxin deprived of the receptor binding domain or functional fragments or derivatives or a biologically active variant thereof; and b) at least one surface immunoglobulin (sIg) B-cell targeting peptide or functional fragments or derivatives or a biologically active variant thereof. Isolated nucleic acids, vectors and pharmaceutical compositions related to said fusion protein, as well as their medical uses, are also objects of the invention.

Provided is an E. coli cell for the production of a Diphtheria toxin polypeptide or mutated form thereof, such as the toxoid CRM197 polypeptide. The E. coli's endogenous gene encoding leucine / isoleucine / valine transporter subunit (LivK) is disrupted, deleted, or engineered to encode an affinity tag fused to the LivK and / or the E. coli's endogenous gene encoding maltose transporter subunit (MalE) is disrupted, deleted, or engineered to encode an affinity tag fused to the MalE to facilitate purification of the Diphtheria toxin polypeptide or mutated form thereof from the E. coli.